Cambridge’s T-Therapeutics secures €27.5M to advance Next-Generation Immune Therapies
T-Therapeutics, a UK biotech developing next-generation T cell receptor (TCR) therapies for cancer and autoimmune diseases, has expanded its Series A round with an additional €27.5 million ($32 million) in funding.

The best Articles in our Network